Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Increasing Patient Compliance Today Improves Outcomes Tomorrow

Billions of dollars are spent each year on surgeries, and unintended complications only add to the total.1 The need for effective perioperative care— in hospital patient care prior to and following a surgical procedure— is essential. Proper perioperative care reduces postoperative complications, hospital readmissions, and overall costs. Simply put, employing innovative, best practice perioperative care today…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Billions of dollars are spent each year on surgeries, and unintended complications only add to the total.1 The need for effective perioperative care— in hospital patient care prior to and following a surgical procedure— is essential. Proper perioperative care reduces postoperative complications, hospital readmissions, and overall costs. Simply put, employing innovative, best practice perioperative care today will result in better outcomes for patients and facilities tomorrow.

Enhanced Recovery After Surgery

Enhanced Recovery After Surgery (ERAS) protocols seek to improve perioperative care by comprehensively re-examining traditional practices throughout all steps of the surgical process and replacing them with more effective evidence-based best practices to achieve healthier post-operative results and early patient recovery.2

ERAS addresses the key factors that keep patients in the hospital after surgery— the need for parenteral analgesia, the need for intravenous fluids secondary to gut dysfunction, and bed rest caused by lack of mobility. The program helps clarify how these factors interact to affect patient recovery. Further, ERAS guides medical professionals involved in perioperative care to work together as a cohesive unit to ensure the best possible patient care.

The ERAS Protocol Has Produced Remarkable Results

  • In a study at Ersta Hospital in Stockholm, Sweden, adherence to ERAS was assessed among 953 patients and compared with postoperative outcomes after colorectal cancer surgery.3 High adherence to the ERAS protocol resulted in a 25% lower risk of postoperative complications for patients, and a nearly 50% lower risk of postoperative symptoms delaying discharge, 30-day morbidity, and readmissions.
  • A study of 554 patients at an academic hospital was conducted to assess patient satisfaction, discharge needs, and follow-up concerns within an ERAS program.4 The conclusions showed that improved post-operative education for surgical patients prior to discharge helped decrease unplanned hospital visits during the immediate post-discharge period.
  • The University Hospital of Lausanne, Switzerland, conducted a study to observe and measure nursing workload before, during, and after systematic implementation of a comprehensive ERAS pathway in colorectal surgery.5 Although such intensive protocols are often assumed to increase nursing workload, the study found the opposite. The higher the compliance with the pathway, the lower the burden for the nursing staff.

AliMed Can Help Improve Perioperative Care

To ensure post-operative results remain positive once patients leave the hospital, they must have the tools necessary to comply with their discharge instructions. AliMed’s complete line of Aids for Daily Living, or ADLs, are the high-quality products patients need to fulfill their aftercare treatment plan. Specialized products, such as Joint Recovery KitsHip Kits, and Stroke Kits, not only lead to positive outcomes, but promote patient independence to achieve long-term recovery success and an overall improved quality of life.

To learn more about how AliMed’s wide selection of superior ADLs propel post-operative results while reducing costs and readmissions, visit https://www.alimed.com/adls/ today.

REFERENCES

  1. https://www.debt.org/medical/hospital-surgery-costs/
  2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202008/
  3. https://jamanetwork.com/journals/jamasurgery/fullarticle/407379
  4. https://awww.ncbi.nlm.nih.gov/pubmed/28932946
  5. https://www.journal-surgery.net/article/S1743-9191(15)01290-X/fulltext

Read more at alimed.com

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

NextGen Invent’s Deepak Mittal argues for scoped healthcare AI pilots with early governance

NextGen Invent’s Deepak Mittal argues that healthcare AI pilots can begin with a reliable data subset and early governance. His performance figures are vendor claims, not independently verified results.

  • 01Deepak Mittal advocates starting with a defined problem and suitable data rather than waiting for perfect organization-wide data.
  • 02Some performance figures cited in the interview (for example, preparation time and model counts) are company-reported and not independently verified in this article.
  • 03NIST’s voluntary AI Risk Management Framework provides an independent structure for governance and risk evaluation.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512